Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2025 Earnings Call Transcript February 12, 2026
Ultragenyx Pharmaceutical Inc. misses on earnings expectations. Reported EPS is $-1.29 EPS, expectations were $-1.2.
Operator: Good afternoon, and welcome to the Ultragenyx Fourth Quarter and Full Year 2025 Financial Results Conference Call. [Operator Instructions] It is now my pleasure to turn the call to Joshua Higa, Vice President of Investor Relations.
Joshua Higa: Thank you. We have issued a...
